Phase II Study With PARP Inhibitor Veliparib (ABT-888) in Patients With Increased Risk of Homologous Recombination Deficiency to Determine the Value of an (Ex-vivo) RAD51 Assay as a Biomarker
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 02 May 2018
At a glance
- Drugs Veliparib (Primary)
- Indications Cancer
- Focus Biomarker; Therapeutic Use
- Acronyms REPAIR
- 26 Apr 2018 Planned End Date changed from 1 Aug 2020 to 1 Nov 2020.
- 26 Apr 2018 Planned primary completion date changed from 1 Aug 2020 to 1 Nov 2020.
- 26 Apr 2018 Planned initiation date changed from 1 May 2018 to 1 Nov 2018.